Rocket Pharma Prelim Phase 1 Anemia Trial Results at ASH19

—US Phase 1 Trial Establishes Feasibility of Commercial “Process B” Vector/Cell Manufacturing in FA—

—Preliminary Data Demonstrate Evidence of Early Engraftment Without Conditioning Four to Six Months after Administration of Gene Therapy—

—“Process B” Drug Product VCN 2-3x Higher Than That Administered to Optimally-Treated “Process A” Patients—

https://www.marketscreener.com/ROCKET-PHARMACEUTICALS-I-40561561/news/Rocket-Pharmaceuticals-Presents-Promising-Preliminary-Results-from-Phase-1-Trial-of-Commercial-Gra-29698574/